OBJECTIVE: To test the efficacy of standardised monitoring using the disease activity index DAS28 versus usual care on disease modifying antirheumatic drug (DMARD) prescription and disease activity in rheumatoid arthritis. METHODS: A 24 week cluster randomised trial. Rheumatology outpatient centres were randomised to systematic monitoring of disease activity using the DAS28 (12 centres, 205 patients) or usual care (12 centres, 179 patients). The aim for the DAS group was to reach a DAS28 score of < or =3.2 by changes in DMARD treatment, at the discretion of the rheumatologist and the patient. RESULTS: At baseline, disease activity was the same in both groups, with an overall mean (SD) DAS28 of 4.5 (1.2); 13% of the patients had a DAS28 of < or =3.2. At 24 weeks, 31% of patients in the DAS group had a DAS28 < or =3.2, while in the usual care centres this was 16% (p = 0.028). DMARDs were changed on average in 18% of visits in the DAS centres; in the 12 usual care centres they were changed on 8% of the visits (p = 0.013). The doses of methotrexate, sulfasalazine, and corticosteroids appeared to be higher in the DAS centres than in the usual care centres, but the differences were not significant. CONCLUSIONS: In daily practice, systematic monitoring of disease activity in rheumatoid arthritis may lead to more changes in DMARD treatment, resulting in a larger number of patients with low disease activity.
RCT Entities:
OBJECTIVE: To test the efficacy of standardised monitoring using the disease activity index DAS28 versus usual care on disease modifying antirheumatic drug (DMARD) prescription and disease activity in rheumatoid arthritis. METHODS: A 24 week cluster randomised trial. Rheumatology outpatient centres were randomised to systematic monitoring of disease activity using the DAS28 (12 centres, 205 patients) or usual care (12 centres, 179 patients). The aim for the DAS group was to reach a DAS28 score of < or =3.2 by changes in DMARD treatment, at the discretion of the rheumatologist and the patient. RESULTS: At baseline, disease activity was the same in both groups, with an overall mean (SD) DAS28 of 4.5 (1.2); 13% of the patients had a DAS28 of < or =3.2. At 24 weeks, 31% of patients in the DAS group had a DAS28 < or =3.2, while in the usual care centres this was 16% (p = 0.028). DMARDs were changed on average in 18% of visits in the DAS centres; in the 12 usual care centres they were changed on 8% of the visits (p = 0.013). The doses of methotrexate, sulfasalazine, and corticosteroids appeared to be higher in the DAS centres than in the usual care centres, but the differences were not significant. CONCLUSIONS: In daily practice, systematic monitoring of disease activity in rheumatoid arthritis may lead to more changes in DMARD treatment, resulting in a larger number of patients with low disease activity.
Authors: Paco M J Welsing; Robert B M Landewé; Piet L C M van Riel; Maarten Boers; Anke M van Gestel; Sjef van der Linden; Hilde L Swinkels; Désirée M F M van der Heijde Journal: Arthritis Rheum Date: 2004-07
Authors: J Fransen; G Stucki; J Twisk; A-M Chamot; J-C Gerster; T Langenegger; M Seitz; B A Michel Journal: Ann Rheum Dis Date: 2003-07 Impact factor: 19.103
Authors: G A Matricali; A Boonen; J Verduyckt; V Taelman; P Verschueren; A Sileghem; L Corluy; R Westhovens Journal: Ann Rheum Dis Date: 2006-09 Impact factor: 19.103
Authors: Klaus P Machold; Hans Peter Brezinsek; Burkhard F Leeb; Stephan Pflugbeil; Franz Rainer; Franz Singer; Martin Skoumal; Tanja A Stamm; Manfred Herold Journal: Wien Klin Wochenschr Date: 2008 Impact factor: 1.704
Authors: Stéphane Genevay; Christine Cedraschi; Marc Marty; Sylvie Rozenberg; Pierre De Goumoëns; Antonio Faundez; Federico Balagué; François Porchet; Anne F Mannion Journal: Eur Spine J Date: 2011-09-01 Impact factor: 3.134
Authors: Daniel H Solomon; Elena Losina; Bing Lu; Agnes Zak; Cassandra Corrigan; Sara B Lee; Jenifer Agosti; Asaf Bitton; Leslie R Harrold; Theodore Pincus; Helga Radner; Zhi Yu; Josef S Smolen; Liana Fraenkel; Jeffrey N Katz Journal: Arthritis Rheumatol Date: 2017-05-31 Impact factor: 10.995